Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results
Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…